陈崇 - 四川大学 - 生物治疗国家重点实验室

个人简介

2015年国家自然科学基金优秀青年基金项目获得者陈崇教授1999年毕业于北京大学生命科学学院获学士学位，2009 年毕业于（美国）密歇根大学细胞与发育生物学系，获博士学位。2010-2014年在（美国）冷泉港实验室、纪念斯隆凯特琳癌症中心的Scott Lowe实验室从事博士后工作。2014 年8 月受聘于在四川大学华西医院/生物治疗国家重点实验室。

研究领域

1. 恶性肿瘤发生发展的分子机制； 2. 成体干细胞的维持、恶性转变和衰老的分子机制； 3. CRISPR/Cas9基因编辑 4. 类器官培养及应用 5. 表观遗传学在肿瘤和成体干细胞中的调控作用； 6. 染色体异常在肿瘤中的作用及靶向治疗

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Liu, Yu＃, Chen, C. ＃,Xu, Z.,Scuoppo, C., Rillahan, CD.,Gao,J., Spitzer, B., Bosbach, B., Kastenhubr, ER., Baslan, T., Ackermann, S., Cheng, L., Wang, Q., Niu, T., Schultz, N., Levine, RL., Mills, AA.& Lowe, SW., Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.2016, Nature, 531:471-5. (#共同第一) 2. Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 functions as a chromosome 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 2014 May 12; 25(5): 652-665. 3. Chen C, Liu Y, Lu C, Cross JR, Morris JP 4th, Shroff AS, Ward PS, Bradner JE, Thompson C, Lowe SW. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 2013 Sep 15;27(18):1974-85. 4. Chen C, Liu Y, Liu Y*, Zheng P*. mTOR Activation Underlies Hematopoietic Stem Cell Defects in Autoimmune Diseases and Inflammation in the Mice. Journal of Clinical Investigation 2010 Nov 1;120(11):4091-101. （*共同通讯） 5. Chen C. microRNAs in myelodysplastic syndromes: How much do we know and not know? Leuk Res. 2013 Mar;37(3):241-2. 6. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y*, Zheng P*. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med. 2008 Sep 29;205(10):2397-408. （*共同通讯） 7. Chen C, Liu Y, Liu Y*, Zheng P*. 2009. mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells. Science Signaling 2009 Nov 24;2(98): ra75. （*共同通讯） 8. Chen C, Liu Y, Liu Y, Zheng P. mTOR-mitochondria-ROS axis and stemness of the hematopoietic stem cells. Cell Cycle 2009 Apr 15;8(8):1158-60. 9. Li CS*, Chen C*, Zheng P*, Liu Y*. Transgenic expression of P1A induced thymic tumor: a role for onco-fetal antigens in tumorigenesis. PLoS One. 2010 Oct 15;5(10):e13439. (* co-first author) （*共同通讯） 10. Ye P.*, Liu Y.*, Chen C, Liu Y*., Zheng P*. An mTOR-Mdm2-Drosha Pathway for miRNA Biogenesis in Hematopoiesis and Cellular Response to Glucose Deprivation. Molecular Cell. 2015 Feb 19;57(4):708-20. (*: co-first author) （*共同通讯） 11. Lu C, Venneti S, Akalin A, Fang F, Ward PS, Dematteo RG, Intlekofer AM, Chen C, Ye J, Hameed M, Nafa K, Agaram NP, Cross JR, Khanin R, Mason CE, Healey JH, Lowe SW, Schwartz GK, Melnick A, Thompson CB. Induction of sarcomas by mutant IDH2. Genes Dev. 2013 Sep 15;27(18):1986-98. 12. Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, Qu J, Fang D, Wu W, Bai XF, Liu JQ, Woodiga SA, Chen C, Sun L, Hogaboam CM, Kunkel SL, Zheng P*, Liu Y*. Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction. Nat Biotechnol. 2011 May;29(5):428-35. （*共同通讯） 13. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, Fellmann C, Taylor MJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011 Aug 1;25(15):1628-40. 14. Wang LZ, Liu RH, Li W, Chen C, Katoh H, Chen GY, McNally BA, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y*, Zheng P*. 2009. Somatic Single-hits Inactivate the X-linked Tumor Suppressor FOXP3 in the Prostate. Cancer Cell 2009 Oct 6;16(4):336-46. （*共同通讯） 15.Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ.Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood. 2015 Feb 26;125(9):1444-51. 16. Wong C.*, Chen C, Liu Y*, Zheng P*. A critical Role for Regulated Wnt-Myc pathway in Naïve T cells Survival. J Immunol. 2015 Jan 1;194(1):158-67（*共同通讯） 17. Wu Q, Liu Y, Chen C, Ikenoue T, Qiao Y, Li CS, Li W, Guan KL, Liu Y*, Zheng P*. The tuberous sclerosis complex-mammalian target of rapamycin pathway maintains the quiescence and survival of naive T cells. J Immunol. 2011 Aug 1;187(3):1106-12. （*共同通讯） 18. Fennell M, Xiang Q, Hwang A, Chen C, Huang CH, Chen CC, Pelossof R, Garippa RJ. Impact of RNA-guided technologies for target identification and deconvolution. J Biomol Screen. 2014 Dec;19(10):1327-37.